HIM
LIMNW

HGC Investment Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

HGC Investment Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94 Hold
1,250
– – ﹤0.01% 180
2026
Q1 		$50 Hold
1,250
– – ﹤0.01% 165
2025
Q4 		$44 Hold
1,250
– – ﹤0.01% 158
2025
Q3 		$185 Hold
1,250
– – ﹤0.01% 121
2025
Q2 		$300 Buy
+1,250
New +$246 ﹤0.01% 98

Other funds holding LIMNW

Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Saba Capital Management
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Moore Capital Management
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LMR Partners
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

HGC Investment Management's LIMNW Position: Q2 2026 in Review

HGC Investment Management held its Liminatus Pharma Warrants (LIMNW) position steady in Q2 2026 at 1,250 shares worth $94. The position accounts for ﹤0.01% of the portfolio, ranked #180.

HGC Investment Management first reported a position in LIMNW in Q2 2025 and has held it in 5 quarters since. The position peaked at $300 in Q2 2025. 22 funds tracked by Wall St. Rank hold LIMNW as of Q2 2026.

  • HGC Investment Management held 1,250 shares of Liminatus Pharma Warrants worth $94 as of Q2 2026.
  • HGC Investment Management left its Liminatus Pharma Warrants share count unchanged in Q2 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of HGC Investment Management's portfolio in Q2 2026, its #180 holding.
  • HGC Investment Management first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 5 quarters since.
  • HGC Investment Management's Liminatus Pharma Warrants position peaked at $300 in Q2 2025.
  • 22 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q2 2026.

Based on HGC Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.